Skip to main content
. 2016 Feb 23;11(2):e0147922. doi: 10.1371/journal.pone.0147922

Fig 2. The geographical distribution of (A) HCV antibody prevalence and (B) proportion of injecting drug use among MMT clients with baseline HCV test results in China.

Fig 2